Oral phycocyanobilin may diminish the pathogenicity of activated brain microglia in neurodegenerative disorders

Medical Hypotheses

Volumn 74, Issue 3, 2010, Pages 601-605

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANGIOTENSIN II; BRAIN PROTEIN; C PHYCOCYANIN; CENTRAL NERVOUS SYSTEM AGENTS; EXCITOTOXIN; NEUROPROTECTIVE AGENT; PHYCOCYANOBILIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; VITAMIN D;

ANALGESIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL FUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HYPERALGESIA; MICROGLIA; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENICITY; PHYSIOLOGICAL PROCESS; PROTEIN FUNCTION; RISK REDUCTION; SPIRULINA; STROKE;

ADMINISTRATION, ORAL; ANIMALS; BRAIN; COMPUTER SIMULATION; HUMANS; MICE; MICROGLIA; MODELS, NEUROLOGICAL; NADPH OXIDASE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PHYCOBILINS; PHYCOCYANIN; RATS; SIGNAL TRANSDUCTION;

MUS; PARKINSONIA; RATTUS; RODENTIA; SPIRULINA;

EID: 77649269960     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.09.061     Document Type: Article

References (105)

1. Terry M.J., Maines M.D., Lagarias J.C. Inactivation of phytochrome- and phycobiliprotein-chromophore precursors by rat liver biliverdin reductase. J Biol Chem 1993, 268:26099-26106.
2. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005, 19:1890-1892.
3. Matsumoto H., Ishikawa K., Itabe H., Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 2006, 291:21-28.
4. Jiang F., Roberts S.J., Datla S., Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006, 48:950-957.
5. Otterbein L.E., Soares M.P., Yamashita K., Bach F.H. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 2003, 24:449-455.
6. Novotny L., Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003, 228:568-571.
7. Vitek L., Jirsa M., Brodanova M., Kalab M., Marecek Z., Danzig V., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002, 160:449-456.
8. Vitek L., Novotny L., Sperl M., Holaj R., Spacil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006, 21:408-414.
9. McCarty M.F. "Iatrogenic Gilbert sydrome" - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007, 69:974-994.
10. Romay C., Armesto J., Remirez D., Gonzalez R., Ledon N., Garcia I. Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998, 47:36-41.
11. Romay C., Delgado R., Remirez D., Gonzalez R., Rojas A. Effects of phycocyanin extract on tumor necrosis factor-alpha and nitrite levels in serum of mice treated with endotoxin. Arzneimittelforschung 2001, 51:733-736.
12. Romay C., Gonzalez R., Ledon N., Remirez D., Rimbau V. C-phycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci 2003, 4:207-216.
13. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26:349-354.
14. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
15. McCarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses 2006, 67:251-269.
16. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci USA 2005, 102:9936-9941.
17. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T., et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 2000, 273:5-9.
18. Gao H.M., Hong J.S., Zhang W., Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002, 22:782-790.
19. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
20. Qin L., Liu Y., Cooper C., Liu B., Wilson B., Hong J.S. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002, 83:973-983.
21. Gao H.M., Liu B., Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003, 23:6181-6187.
22. Gao H.M., Liu B., Zhang W., Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 2003, 17:1954-1956.
23. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004, 279:1415-1421.
24. Vaziri N.D., Lee Y.S., Lin C.Y., Lin V.W., Sindhu R.K. NAD(P)H oxidase, superoxide dismutase, catalase, glutathione peroxidase and nitric oxide synthase expression in subacute spinal cord injury. Brain Res 2004, 995:76-83.
25. Wu X.F., Block M.L., Zhang W., Qin L., Wilson B., Zhang W.Q., et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 2005, 7:654-661.
26. Mander P., Brown G.C. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation 2005, 2:20.
27. Qin L., Liu Y., Qian X., Hong J.S., Block M.L. Microglial NADPH oxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann NY Acad Sci 2005, 1053:107-120.
28. Choi S.H., Lee D.Y., Chung E.S., Hong Y.B., Kim S.U., Jin B.K. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 2005, 95:1755-1765.
29. Wu D.C., Re D.B., Nagai M., Ischiropoulos H., Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci USA 2006, 103:12132-12137.
30. Wang T., Qin L., Liu B., Liu Y., Wilson B., Eling T.E., et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 2004, 88:939-947.
31. Min K.J., Pyo H.K., Yang M.S., Ji K.A., Jou I., Joe E.H. Gangliosides activate microglia via protein kinase C and NADPH oxidase. Glia 2004, 48:197-206.
32. Pawate S., Shen Q., Fan F., Bhat N.R. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 2004, 77:540-551.
33. Sawada M., Imamura K., Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2006, 373-381.
34. Qin L., Block M.L., Liu Y., Bienstock R.J., Pei Z., Zhang W., et al. Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550-557.
35. Torreilles F., Salman-Tabcheh S., Guerin M., Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Brain Res Rev 1999, 30:153-163.
36. Boven L.A., Gomes L., Hery C., Gray F., Verhoef J., Portegies P., et al. Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. J Immunol 1999, 162:4319-4327.
37. Urushitani M., Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:71-81.
38. Ebadi M., Sharma S.K. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal 2003, 5:319-335.
39. Salvemini D., Jensen M.P., Riley D.P., Misko T.P. Therapeutic manipulations of peroxynitrite. Drug News Perspect 1998, 11:204-214.
40. Pehar M., Vargas M.R., Robinson K.M., Cassina P., England P., Beckman J.S., et al. Peroxynitrite transforms nerve growth factor into an apoptotic factor for motor neurons. Free Radic Biol Med 2006, 41:1632-1644.
41. Sawada M., Imamura K., Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2006, 373-381.
42. Rimbau V., Camins A., Romay C., Gonzalez R., Pallas M. Protective effects of C-phycocyanin against kainic acid-induced neuronal damage in rat hippocampus. Neurosci Lett 1999, 276:75-78.
43. Patel M., Li Q.Y., Chang L.Y., Crapo J., Liang L.P. Activation of NADPH oxidase and extracellular superoxide production in seizure-induced hippocampal damage. J Neurochem 2005, 92:123-131.
44. Chamorro G., Perez-Albiter M., Serrano-Garcia N., Mares-Samano J.J., Rojas P. Spirulina maxima pretreatment partially protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Nutr Neurosci 2006, 9:207-212.
45. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003, 100:6145-6150.
46. Tieu K., Ischiropoulos H., Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 2003, 55:329-335.
47. Zhang W., Wang T., Qin L., Gao H.M., Wilson B., Ali S.F., et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004, 18:589-591.
48. Salazar M., Martinez E., Madrigal E., Ruiz L.E., Chamorro G.A. Subchronic toxicity study in mice fed Spirulina maxima. J Ethnopharmacol 1998, 62:235-241.
49. Salazar M., Chamorro G.A., Salazar S., Steele C.E. Effect of Spirulina maxima consumption on reproduction and peri- and postnatal development in rats. Food Chem Toxicol 1996, 34:353-359.
50. Tammariello S.P., Quinn M.T., Estus S. NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. J Neurosci 2000, 20:RC53.
51. Noh K.M., Koh J.Y. Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci 2000, 20:RC111.
52. Hwang J.J., Choi S.Y., Koh J.Y. The role of NADPH oxidase, neuronal nitric oxide synthase and poly(ADP ribose) polymerase in oxidative neuronal death induced in cortical cultures by brain-derived neurotrophic factor and neurotrophin-4/5. J Neurochem 2002, 82:894-902.
53. Kim S.H., Won S.J., Sohn S., Kwon H.J., Lee J.Y., Park J.H., et al. Brain-derived neurotrophic factor can act as a pronecrotic factor through transcriptional and translational activation of NADPH oxidase. J Cell Biol 2002, 159:821-831.
54. Serrano F., Kolluri N.S., Wientjes F.B., Card J.P., Klann E. NADPH oxidase immunoreactivity in the mouse brain. Brain Res 2003, 988:193-198.
55. Wang G., Anrather J., Huang J., Speth R.C., Pickel V.M., Iadecola C. NADPH oxidase contributes to angiotensin II signaling in the nucleus tractus solitarius. J Neurosci 2004, 24:5516-5524.
56. Hilburger E.W., Conte E.J., McGee D.W., Tammariello S.P. Localization of NADPH oxidase subunits in neonatal sympathetic neurons. Neurosci Lett 2005, 377:16-19.
57. Vallet P., Charnay Y., Steger K., Ogier-Denis E., Kovari E., Herrmann F., et al. Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. Neuroscience 2005, 132:233-238.
58. Tejada-Simon M.V., Serrano F., Villasana L.E., Kanterewicz B.I., Wu G.Y., Quinn M.T., et al. Synaptic localization of a functional NADPH oxidase in the mouse hippocampus. Mol Cell Neurosci 2005, 29:97-106.
59. Dai X., Cao X., Kreulen D.L. Superoxide anion is elevated in sympathetic neurons in DOCA-salt hypertension via activation of NADPH oxidase. Am J Physiol Heart Circ Physiol 2006, 290:H1019-H1026.
60. Jana A., Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. implications for Alzheimer's disease. J Biol Chem 2004, 279:51451-51459.
61. Jana A., Pahan K. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci 2004, 24:9531-9540.
62. Kim Y.H., Koh J.Y. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture. Exp Neurol 2002, 177:407-418.
63. Pietri M., Caprini A., Mouillet-Richard S., Pradines E., Ermonval M., Grassi J., et al. Overstimulation of PrPC signaling pathways by prion peptide 106-126 causes oxidative injury of bioaminergic neuronal cells. J Biol Chem 2006, 281:28470-28479.
64. Abramov A.Y., Scorziello A., Duchen M.R. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J Neurosci 2007, 27:1129-1138.
65. Nikolova S., Lee Y.S., Lee Y.S., Kim J.A. Rac1-NADPH oxidase-regulated generation of reactive oxygen species mediates glutamate-induced apoptosis in SH-SY5Y human neuroblastoma cells. Free Radic Res 2005, 39:1295-1304.
66. Walder C.E., Green S.P., Darbonne W.C., Mathias J., Rae J., Dinauer M.C., et al. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 1997, 28:2252-2258.
67. Wang Q., Tompkins K.D., Simonyi A., Korthuis R.J., Sun A.Y., Sun G.Y. Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. Brain Res 2006, 1090:182-189.
68. Hong H., Zeng J.S., Kreulen D.L., Kaufman D.I., Chen A.F. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol 2006, 291:H2210-H2215.
69. Chan S.H., Hsu K.S., Huang C.C., Wang L.L., Ou C.C., Chan J.Y. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. Circ Res 2005, 97:772-780.
70. Zimmerman M.C., Dunlay R.P., Lazartigues E., Zhang Y., Sharma R.V., Engelhardt J.F., et al. Requirement for Rac1-dependent NADPH oxidase in the cardiovascular and dipsogenic actions of angiotensin II in the brain. Circ Res 2004, 95:532-539.
71. Kim-Mitsuyama S., Yamamoto E., Tanaka T., Zhan Y., Izumi Y., Izumiya Y., et al. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke 2005, 36:1083-1088.
72. Ma X., Zhang H.J., Whiteis C.A., Tian X., Davisson R.L., Kregel K.C., et al. NAD(P)H oxidase-induced oxidative stress in sympathetic ganglia of apolipoprotein E deficient mice. Auton Neurosci 2006, 126-127:285-291.
73. Pflueger A., Croatt A.J., Peterson T.E., Smith L.A., d'Uscio L.V., Katusic Z.S., et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005, 288:F552-F558.
74. McCarty M.F. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke - just say NO to stroke!. Med Hypotheses 2000, 55:386-403.
75. Tal M. A novel antioxidant alleviates heat hyperalgesia in rats with an experimental painful peripheral neuropathy. Neuroreport 1996, 7:1382-1384.
76. Khalil Z., Liu T., Helme R.D. Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. Pain 1999, 79:31-37.
77. Wang Z.Q., Porreca F., Cuzzocrea S., Galen K., Lightfoot R., Masini E., et al. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther 2004, 309:869-878.
78. Naik A.K., Tandan S.K., Dudhgaonkar S.P., Jadhav S.H., Kataria M., Prakash V.R., et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-l-cysteine in rats. Eur J Pain 2006, 10:573-579.
79. Sayyed S.G., Kumar A., Sharma S.S. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sci 2006, 79:777-783.
80. Khattab M.M. TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. Eur J Pharmacol 2006, 548:167-173.
81. Puntambekar P., Mukherjea D., Jajoo S., Ramkumar V. Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression. J Neurochem 2005, 95:1689-1703.
82. Obata K., Katsura H., Mizushima T., Yamanaka H., Kobayashi K., Dai Y., et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest 2005, 115:2393-2401.
83. Kishida K.T., Pao M., Holland S.M., Klann E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J Neurochem 2005, 94:299-306.
84. Klann E. Cell-permeable scavengers of superoxide prevent long-term potentiation in hippocampal area CA1. J Neurophysiol 1998, 80:452-457.
85. Thiels E., Urban N.N., Gonzalez-Burgos G.R., Kanterewicz B.I., Barrionuevo G., Chu C.T., et al. Impairment of long-term potentiation and associative memory in mice that overexpress extracellular superoxide dismutase. J Neurosci 2000, 20:7631-7639.
86. Knapp L.T., Klann E. Role of reactive oxygen species in hippocampal long-term potentiation: contributory or inhibitory?. J Neurosci Res 2002, 70:1-7.
87. Heusler P., Boehmer G. The superoxide anion is involved in the induction of long-term potentiation in the rat somatosensory cortex in vitro. Brain Res 2004, 1024:104-112.
88. Wang Q., Rowan M.J., Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 2004, 24:6049-6056.
89. Rowan M.J., Klyubin I., Wang Q., Anwyl R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp Gerontol 2004, 39:1661-1667.
90. McGahon B.M., Martin D.S., Horrobin D.F., Lynch M.A. Age-related changes in LTP and antioxidant defenses are reversed by an alpha-lipoic acid-enriched diet. Neurobiol Aging 1999, 20:655-664.
91. Hu D., Serrano F., Oury T.D., Klann E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J Neurosci 2006, 26:3933-3941.
92. Kishida K.T., Hoeffer C.A., Hu D., Pao M., Holland S.M., Klann E. Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. Mol Cell Biol 2006, 26:5908-5920.
93. Klivenyi P., Gardian G., Calingasan N.Y., Yang L., Beal M.F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 2003, 21:191-198.
94. Klivenyi P., Kiaei M., Gardian G., Calingasan N.Y., Beal M.F. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004, 88:576-582.
95. Mattson M.P., Duan W., Wan R., Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. Neurorx 2004, 1:111-116.
96. Neveu I., Naveilhan P., Menaa C., Wion D., Brachet P., Garabedian M. Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. J Neurosci Res 1994, 38:214-220.
97. Garcion E., Sindji L., Montero-Menei C., Andre C., Brachet P., Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 1998, 22:282-294.
98. Garcion E., Nataf S., Berod A., Darcy F., Brachet P. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res 1997, 45:255-267.
99. Lefebvre dC, Montero-Menei C.N., Bernard R., Couez D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. J Neurosci Res 2003, 71:575-582.
100. Kim J.S., Kim Y.I., Song C., Yoon I., Park J.W., Choi Y.B., et al. Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci 2005, 20:495-498.
101. Newmark H.L., Newmark J. Vitamin D and Parkinson's disease-A hypothesis. Mov Disord 2007.
102. Sato Y., Asoh T., Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone 1998, 23:555-557.
103. Bondy S.C., Sharman E.H. Melatonin and the aging brain. Neurochem Int 2007.
104. McCarty M.F., Falahati-Nini A. Neuroprotective potential of the Bahadori leanness program: a "mini-fast with exercise" strategy. Med Hypotheses 2006.
105. McCarty M.F. Toward prevention of Alzheimers disease - potential nutraceutical strategies for suppressing the production of amyloid beta peptides. Med Hypotheses 2006, 67:682-697.